How big is Aquestive Therapeutics, Inc.?

As of Jun 18, Aquestive Therapeutics, Inc. has a market capitalization of 332.75 million and reported net sales of 54.23 million with a net profit of -54.24 million over the latest four quarters. The company's balance sheet shows shareholder's funds of -60.16 million and total assets of 101.42 million.

As of Jun 18, Aquestive Therapeutics, Inc. has a market capitalization of 332.75 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 54.23 million for the latest four quarters. During the same period, it experienced a net profit of -54.24 million.<BR><BR>As of Dec 24, the company's balance sheet shows shareholder's funds of -60.16 million and total assets of 101.42 million.

What does Aquestive Therapeutics, Inc. do?

Aquestive Therapeutics, Inc. is a specialty pharmaceutical company focused on CNS disease treatments, with a market cap of $332.75 million and recent net sales of $9 million, but a net loss of $23 million. The company has no dividend yield and a negative price-to-book ratio.

Overview: <BR>Aquestive Therapeutics, Inc. is a specialty pharmaceutical company focused on developing treatments for diseases related to the central nervous system (CNS) within the micro-cap market.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 9 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -23 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 332.75 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.84 <BR>Return on Equity: 89.02% <BR>Price to Book: -5.46<BR><BR>Contact Details: <BR>Address: 30 Technology Dr, WARREN NJ: 07059-5166 <BR>Tel: 1 908 9411900 <BR>Website: https://aquestive.com/

Should I buy, sell or hold Aquestive Therapeutics, Inc.?

Who are in the management team of Aquestive Therapeutics, Inc.?

As of March 2022, the management team of Aquestive Therapeutics, Inc. includes Mr. Santo Costa (Independent Chairman), Mr. Keith Kendall (CEO), Mr. John Cochran (Vice Chairman), and several independent directors: Mr. Douglas Bratton, Dr. Gregory Brown, Ms. Nancy Lurker, and Mr. James Scibetta. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Aquestive Therapeutics, Inc. includes the following individuals:<BR><BR>- Mr. Santo Costa, Independent Chairman of the Board<BR>- Mr. Keith Kendall, President, Chief Executive Officer, and Director<BR>- Mr. John Cochran, Vice Chairman of the Board<BR>- Mr. Douglas Bratton, Independent Director<BR>- Dr. Gregory Brown, Independent Director<BR>- Ms. Nancy Lurker, Independent Director<BR>- Mr. James Scibetta, Independent Director<BR><BR>This team is responsible for guiding the strategic direction and operations of the company.

Is Aquestive Therapeutics, Inc. technically bullish or bearish?

As of September 4, 2025, Aquestive Therapeutics, Inc. is in a bullish trend with strong moving averages and MACD indicators, despite a bearish weekly RSI, and has outperformed the S&P 500 with a year-to-date return of 38.76%.

As of 4 September 2025, the technical trend for Aquestive Therapeutics, Inc. has changed from mildly bullish to bullish. The current stance is bullish with a strong indication from the moving averages, which are bullish on the daily timeframe. The MACD is also bullish on both the weekly and monthly timeframes. However, the weekly RSI is bearish, indicating some short-term weakness. <BR><BR>Overall, the stock has shown a strong performance year-to-date with a return of 38.76%, significantly outperforming the S&P 500's 12.22% during the same period.